The norovirus Phase 3 failure is a material pipeline setback that will likely dominate the narrative and pressure the stock near-term, despite the modest financial beat. Watch for the August 5 PDUFA decision on mFLUSIVA as a potential offsetting catalyst. The improved cash guidance provides some downside protection, but the pipeline read-through is negative.
Drugs in focus
MRNA drug pipeline →mRNA-1010
▲ Bullish Named in this 8-K- Impact
- Phase
- Filed / PDUFA (Phase 3 completed)
- Time to market
- PDUFA date is August 5, 2026. If approved, the vaccine could be available for the 2026/2027 Northern Hemisphere flu season. Regulatory submissions are also under review in Europe, Canada, and Australia, with potential approvals expected in 2026.
- Next catalyst
- None dated
What to watchWatch for the FDA decision by August 5, 2026. The unanimous 9-0 advisory committee vote on June 18 makes approval the base case, and the stock has already re-rated from a 52-week low of $22 to ~$71 on the expectation, so a positive decision may be partially priced in. Approval would unlock a new multi-billion-dollar TAM for Moderna beyond COVID; a surprise CRL would be a severe setback for the stock given how much of the 2026 rally is built on flu vaccine hopes.
How the stock moved after the report
NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · Jul 31 $54.82entry
- T+1 · 4mo ago +0.48%α −0.93% · $55.08
- T+5 · 3mo ago +7.94%α +4.42% · $59.17
- T+20 · 3mo ago +151.71%α +148.73% · $137.99
- T+60 · 22d ago +262.73%α +260.28% · $198.85
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Moderna reported Q2 2026 revenue of $145M (vs $103.9M consensus) and GAAP EPS of -$1.97 (vs -$2.06 consensus), a modest beat on both lines. The company reiterated its plan for up to 10% revenue growth in 2026 and improved its operating expense and year-end cash guidance. However, the norovirus vaccine candidate mRNA-1403 failed a Phase 3 interim analysis, a significant pipeline setback that will likely overshadow the financial beat and weigh on sentiment.
Key Financial Metrics
Key Facts
- Q2 2026 revenue of $145M, up 2% YoY from $142M, beating consensus of $103.9M.
- GAAP EPS of -$1.97, beating consensus of -$2.06 by 4.4%.
- Norovirus vaccine candidate mRNA-1403 failed Phase 3 interim analysis; trial ongoing with additional cohort enrollment.
- 2026 R&D expense guidance lowered to ~$2.9B from ~$3.0B; year-end cash guidance improved to $4.7-5.2B.
- mFLUSIVA (seasonal flu vaccine) has a PDUFA date of August 5, 2026, with potential to become the fifth approved product.
- Cash, cash equivalents and investments at $6.9B as of June 30, 2026, down from $7.5B at March 31, 2026.
Financial Impact
Revenue beat of ~$41M vs consensus; EPS beat of $0.09 vs consensus. Norovirus pipeline failure removes a key growth catalyst.
Risk Factors
- Norovirus vaccine failure removes a key pipeline catalyst and raises questions about the broader vaccine platform's success rate.
- Revenue growth remains heavily dependent on COVID vaccine sales, which are declining year-over-year.
- The company has a history of high cash burn; the improved guidance still implies significant cash consumption.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001682852-26-000147 |
| Document: mrna-20260731.htm | 0001682852-26-000147 |
| Document: 0001682852-26-000147-index-headers.html | 0001682852-26-000147 |
| Document: 0001682852-26-000147-index.html | 0001682852-26-000147 |
| Document: 0001682852-26-000147.txt | 0001682852-26-000147 |
| 8-K Data (Synthetic) | 0001682852-26-000147 |
Track record
26 reports on MRNA
6 of 8 bullish or bearish reports moved the stock their way by T+1. Best: +14.15% at T+60 after the Mar 5, 2026 report. 7 of 8 went positive at some point.
Filters
- Nov 16, 2026today 144 Neutral 3/10 Entry $217.29 Now $215.27 −0.93% settles Nov 17
- Nov 13, 20263d ago 8-K Neutral 3/10 Entry $222.50 Now $215.27 −3.25% settles Nov 17
- Nov 6, 202610d ago 8-K Bullish 7/10 Entry $254.19 to $269.00 Now $215.27 −15.31% ▲ +5.83% +3.46% vs SPY
- Nov 5, 202611d ago SC 13G/A Neutral 3/10 Entry $241.46 to $254.19 Now $215.27 −10.85% ▲ +5.27% +4.96% vs SPY
- Oct 28, 202619d ago Institutional Cluster Neutral 3/10 Entry $214.17 to $222.76 Now $215.27 +0.52% ▲ +4.01% +4.40% vs SPY
- Oct 27, 202620d ago ANALYST-DOWNGRADE Bearish 4/10 Entry $207.97 to $214.17 Now $215.27 −3.51% ▼ −2.98% −2.63% vs SPY
- Sep 30, 20266w ago 8-K Neutral 3/10 Entry $192.57 to $188.94 Now $215.27 +11.79% ▼ −1.89% −2.06% vs SPY
- Sep 30, 20266w ago ANALYST-DOWNGRADE Bearish 4/10 No price data
- Sep 16, 20268w ago Insider Cluster Bearish 5/10 Entry $158.07 to $154.04 Now $215.27 −36.19% ▲ +2.55% +2.43% vs SPY
- Sep 3, 202610w ago ANALYST-DOWNGRADE Bearish 6/10 Entry $148.87 to $145.55 Now $215.27 −44.60% ▲ +2.23% +1.84% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers